Gastrointestinal stromal tumor surgery
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor surgery On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor surgery |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor surgery |
Overview
The predominant therapy for gastrointestinal stromal tumor is surgical resection. Adjunctive chemotherapy/tyrosine Kinase Inhibitor therapy may be required.
Surgical Therapy
Surgery is the definitive therapy and typically the initial therapy for patients of GIST.
- Surgical resection offers an opportunity to completely cure GIST.
- Laparoscopic resection is the most preferred route of surgery. The indications for surgery include:
- Symptomatic patients with locally advanced or metastatic disease.
- Large lesions and tumors that are technically resectable if the risks of morbidity are acceptable
- Surgical resection of GIST include complete gross resection with with an intact pseudocapsule and negative microscopic margins.
- In GIST, lymph node metastasis is rare and therefore lymphadenectomy of clinically uninvolved nodes is not necessary.
- Most small GISTs (<5 and especially <2 cm) with a low rate of mitosis (<5 dividing cells per 50 high-power fields) are benign and, after surgery, do not require adjuvant therapy.
- Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 mitoses/50 HPF), may disseminate and/or recur.
- Until recently, GISTs were notorious for being resistant to chemotherapy, with a success rate of <5%. Recently, the c-kit tyrosine kinase inhibitor imatinib, a drug initially marketed for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.[1]
References